arrow
G

Gualtiero Palareti

AUSL di Bologna
H指数:67
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Descriptive analysis of the Nationwide START2 antiphospholipid registry: Clinical and laboratory characteristics of patients with persistently positive antiphospholipid antibodies

全国性START2抗磷脂抗体登记研究的描述性分析:持续阳性抗磷脂抗体患者的临床和实验室特征

2026-08-010
PRE
Effectiveness of direct oral anticoagulants for all-cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

直接口服抗凝剂对房颤超重和肥胖患者全因死亡率及心血管事件的有效性:来自全国性START注册研究的见解

2025-11-130
OAAI
Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

中度/重度慢性肾脏疾病合并心房颤动患者直接口服抗凝剂的实世界应用:一项来自START注册研究的倾向性评分匹配分析

2025-11-030
OAAI
Thrombotic events after vaccination for covid-19 in Italy: a report from the Italian society on thrombosis and haemostasis registry

接种新冠疫苗后发生的血栓事件:来自意大利血栓与止血学会登记系统的报告

2025-07-300
OAAI
More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
2024-09-165
OAAI
ACEF vs PARIS score in Predicting Cardiovascular Events in Patients With Acute Coronary Syndrome: Insights From the START ANTIPLATELET Registry

ACEF与PARIS评分在预测急性冠状动脉综合征患者心血管事件中的比较:START ANTIPLATELET注册研究的见解

2024-08-270
PRE
Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
2024-04-107
OAAI
Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: clinical characteristics, antibody profiles and estimate of the risk of recurrence

首次发生静脉或动脉血栓事件的抗磷脂综合征患者: 临床特征、抗体特征和复发风险评估

2024-04-020
OA
Inappropriate Underdosing of Direct Oral Anticoagulants in Atrial Fibrillation Patients: Results from the START2-AF Registry

房颤患者直接口服抗凝剂剂量不足的不合理现象:START2-AF注册研究结果

2024-03-295
OAAI
Long-Term Outcomes in Two-Year Follow-Up after Primary Treatment in Patients with a Prior Venous Thromboembolic Event: A Prospective, Observational, Real-Life Study
2024-02-271
OAAI